Navigation Links
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Multiple Sclerosis
Date:9/21/2008

t http://www.mslifelines.com for prescribing information.

* The exact correlation between MRI findings and the current or future clinical status of patients, including disability progression, is unknown.

About Merck Serono and multiple sclerosis

Merck Serono is a leader in multiple sclerosis (MS) with Rebif(R) (interferon beta-1a), a disease-modifying drug used to treat relapsing forms of MS, which is registered in more than 80 countries worldwide. Full prescribing information for Rebif(R) can be obtained by contacting the Company or visiting its website. Additional therapeutic options are currently under development at Merck Serono, including oral cladribine, currently in Phase III and potentially the first oral therapy for MS, as well as several products in early stage development. Merck Serono also is taking a leading role in developing an understanding of the role of genetics in MS.

About multiple sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of the nervous system and is the most common, non-traumatic, disabling, neurological disease in young adults. The World Health Organization estimates that up to 2.5 million people suffer from MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

About Merck Serono

Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical and chemical group. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. Its North American business operates in the United States and Canada as EMD Serono.

Merck Serono has leading brands serving patients with cancer (Erbitux(R
'/>"/>

SOURCE Merck Serono
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Brooke Franchise Corporation Announces Selected July Results
3. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
4. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
5. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
6. NBTY Announces Preliminary Unaudited Net Sales Results For August 2007
7. Martek Announces Third Quarter 2007 Financial Results
8. MDS Reports Third Quarter 2007 Results
9. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
10. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... July 03, 2015 , ... ... providers, has been retained to lead a national chief nursing officer recruitment ... executive search firms in the healthcare industry, B. E. Smith has recently placed ...
(Date:7/3/2015)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... Medical Director of its Frisco facility. , “We are pleased to announce that Dr. ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Manzanares ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the ... sweetFrog store located in Mississippi. The premium frozen yogurt chain was listed as #22 ... located at 104 Railroad Avenue, New Albany, MS 38652, will have a grand opening ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... the parking structure retrofit project at the University of Minnesota, they knew it ... that it would also be an award-winning choice: the total energy savings after ...
(Date:7/2/2015)... ... ... As Americans celebrate the Fourth of July outdoors this weekend, local physicians are ... is UV Safety Month, and physicians at American Family Care and AFC Doctors Express ... say most skin cancers can be found early with regular skin exams. Physicians can ...
Breaking Medicine News(10 mins):Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:sweetfrog Opens First Location in Mississippi 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:Local Physicians Warn of Holiday Health Hazards 2Health News:Local Physicians Warn of Holiday Health Hazards 3Health News:Local Physicians Warn of Holiday Health Hazards 4
... prostate cancer treated with a specialized type of ... fewer gastrointestinal complications compared to patients treated with ... study presented November 1, 2010, at the 52nd ... Oncology (ASTRO). , "With survivors living ...
... invasive bladder cancer allows 67 percent of people to be ... This compares to 54 percent of people who receive radiation ... presented at the plenary session, November 1, 2010, at the ... (ASTRO). , "The trial shows that this treatment offers improved ...
... October 25, 2010 The Life Sciences Discovery Fund (LSDF) ... Corporation (NASDAQ: OMER) to discover, develop, and commercialize new ... successful generation of proceeds through partnering and the sales ... the grant would be establishment of a new non-profit ...
... HealthDay Reporter , MONDAY, Oct. 25 (HealthDay News) -- New ... will start sleeping through the night between 2 and 4 ... however, is for the baby,s eight hours of slumber to ... "The most rapid changes in infant sleep were found ...
... immune system genes A team of ... Cambridge, United Kingdom, has shed new light on genetic ... common disorders of pregnancy, specifically recurrent miscarriage, preeclampsia, and ... initiation of a successful pregnancy is the invasion of ...
... pathway that, when blocked, significantly decreases the spread of ... at The University of Texas MD Anderson Children,s Cancer ... in mice decreased metastases in the lungs 15-fold. The ... Sunday in an oral presentation at the 42nd Congress ...
Cached Medicine News:Health News:Highly targeted radiation technique minimizes side effects of prostate cancer treatment 2Health News:Chemotherapy plus radiation prevents bladder cancer recurrences 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 3Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 2Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 3Health News:JCI table of contents: Oct. 25, 2010 2Health News:JCI table of contents: Oct. 25, 2010 3Health News:JCI table of contents: Oct. 25, 2010 4Health News:JCI table of contents: Oct. 25, 2010 5Health News:JCI table of contents: Oct. 25, 2010 6Health News:JCI table of contents: Oct. 25, 2010 7Health News:JCI table of contents: Oct. 25, 2010 8Health News:JCI table of contents: Oct. 25, 2010 9Health News:Researchers find pathway that drives spread of pediatric bone cancer in preclinical studies 2
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/9q4d5d/veterinary_ ... / Animal Vaccines Market by Product, Diseases & Technology ... offering. The global animal vaccines market is ... Million in 2015, at a CAGR of 5.5% from ... growth are growing prevalence of animal diseases, increasing incidences ...
(Date:7/2/2015)... 2015 Legal-Bay LLC, The Lawsuit Settlement Funding ... Goodwin in the Southern District of ... cases against Ethicon for a single trial to take ... the 26 women include claims from the women plaintiffs ... Johnson & Johnson,s Ethicon subsidiary. The cases against Ethicon ...
(Date:7/2/2015)... -- Agreement reinforces ...   ViiV Healthcare and Desano Pharmaceuticals ... in China of dolutegravir. The agreement ... ingredient (API), and will allow ViiV Healthcare to offer a ... the name Tivicay®) for China and ...
Breaking Medicine Technology:Veterinary / Animal Vaccines Market 2015 - Global Forecast to 2020 for the $7.19 Billion Industry 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 2ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 3ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 4ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 5ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 6
... Significance, FRAZER, Pa., May 01, 2007 /PRNewswire-FirstCall/ ... presented today at the 59th Annual,Meeting of ... highlights,data demonstrating that FENTORA(R) (fentanyl buccal tablet) ... pain in patients,with neuropathic pain who are ...
... Inc. (NYSE:DNA),and Biogen Idec, Inc. (Nasdaq:BIIB) announced ... study of Rituxan(R) (rituximab) in,patients with relapsing-remitting ... American Academy of Neurology annual meeting,held in ... targets and,selectively depletes CD20-positive B-cells., "There remains ...
Cached Medicine Technology:Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 2Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 3Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 4Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 5Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 6Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 7Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6
CDIs 2-Panel Abdominal Binders are designed with a foam backing which provides comfort, support and compression without slippage....
Male Compression Vests...
Male Compression Vest, Front Closure...
Ideal for breast compression with adjustable hook and eye closure....
Medicine Products: